Physician profile
Henry X Yu
NPI 1629043096
$1,002,268.71
in general payments reported to CMS, 2019-2025
31 companies · $307K in 2025
The $307K reported for 2025 was more than what 99% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $47K · 2022: $91K · 2023: $252K · 2024: $306K · 2025: $307K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $540K · Consulting Fee: $153K · Travel and Lodging: $121K · Food and Beverage: $40K · Honoraria: $8,755 · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $2,171 · Education: $281.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $539,931.33 |
| Consulting Fee | $153,038.29 |
| Travel and Lodging | $120,550.31 |
| Food and Beverage | $40,170.67 |
| Honoraria | $8,755.30 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $2,171.00 |
| Education | $281.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $258,367.85 | 2021-2025 | Bimzelx, Cimzia |
| Leo Pharma INC. | $143,013.57 | 2021-2025 | Adbry, Anzupgo |
| Pfizer INC. | $111,401.59 | 2021-2025 | |
| Janssen Biotech, INC. | $90,920.57 | 2021-2025 | Tremfya, Simponi, Stelara |
| Abbvie INC. | $73,155.78 | 2021-2025 | |
| Galderma Laboratories, L.P. | $72,001.41 | 2021-2025 | Aklief, Twyneo, Epsolay |
| Dermavant Sciences, INC. | $67,533.44 | 2022-2024 | Vtama, Tapinarof |
| Arcutis Biotherapeutics, INC. | $54,018.15 | 2023-2025 | Zoryve |
| Sun Pharmaceutical Industries INC. | $25,003.88 | 2021-2025 | Ilumya, Winlevi, Absorica Ld |
| Boehringer Ingelheim Pharmaceuticals, INC. | $23,781.56 | 2023-2025 | Spevigo |
| E.R. Squibb & Sons, L.L.C. | $18,795.71 | 2022-2025 | Sotyktu |
| Incyte Corporation | $16,455.98 | 2021-2025 | Opzelura |
| Botanix Sb INC | $10,195.02 | 2025 | Sofdra |
| Janssen Scientific Affairs, LLC | $9,858.87 | 2022-2025 | Tremfya |
| Organon LLC | $9,532.79 | 2025 | Vtama |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $6,260.98 | 2021-2025 | Otezla, Otezla |
| Epi Health, LLC | $3,796.62 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $1,745.75 | 2021-2023 | |
| Regeneron Healthcare Solutions, INC. | $1,672.45 | 2021-2025 | Dupixent, Libtayo |
| Mayne Pharma Commercial LLC | $1,100.00 | 2024 | |
| Sanofi US Services INC. | $1,061.00 | 2025 | |
| Genzyme Corporation | $982.07 | 2021-2025 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $702.14 | 2021-2025 | Cabtreo, Siliq |
| Kowa Pharmaceuticals America, INC. | $400.00 | 2025 | Zoryve |
| Almirall LLC | $185.37 | 2021-2023 | Klisyri |
| Astrazeneca Pharmaceuticals Lp | $127.00 | 2024 | Saphnelo |
| Lilly USA, LLC | $87.49 | 2022-2025 | Ebglyss, Taltz |
| Helsinn Therapeutics (U.S.), INC. | $59.65 | 2021-2025 | Valchlor |
| Biofrontera INC. | $18.41 | 2021 | |
| Sandoz INC. | $17.00 | 2021 | |
| Dermira, INC. | $16.61 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Henry Yu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.